報價延遲最少15分鐘:2025/08/16 04:24 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.01 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.10/-4.82
|
|
企業價值
436.97M
|
| 資產負債 |
|
每股賬面淨值
17.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.32M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/16 04:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities. |
